Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030 WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit. Suarez will lead the execution of the Company’s previously announced $50 billion US research, development and manufacturing investment, including construction of a $4.5 billion manufacturing facility in Virginia, AstraZ

28-day data from global Phase 1 proof-of-concept study of CLY-124 in Sickle Cell Disease expected in Q4 2026 In vivo preclinical data assessing new compounds vs. standard of care in gold-standard, translatable myelofibrosis model expected in Q2 2026 Advancing existing discovery and development collaborations in MASH and IBD Ted Myles, CEO, presenting at J.P. Morgan Healthcare conference on January 12, 2026 at 10:00 a.m. PT (1 p.m. ET) SOMERVILLE, Mass.--(BUSINESS WIRE)--Cellarity, a clinical-sta

SUNRISE, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Transpire Bio announced today that its Chief Executive Officer, Dr. Xian-Ming Zeng, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2026 at 8:00 am Pacific Time. About Transpire Bio Inc. Transpire Bio Inc. is an integrated, US-based, revenue-generating, clinical-stage biopharmaceutical company headquartered in Sunrise, Florida. Transpire Bio harnesses its inhaled drug delivery expertise

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application (BLA) for Sonelokimab (SLK) in Hidradenitis Suppurativa (HS) FDA feedback confirms that the Company may establish substantial evidence of effectiveness (SEE), without additional clinical trials in HS, with a BLA consisting of data from its existing VELA-1, VELA-2 and MIRA trials The FDA specif

iStock, kody king While venture capital funding dipped to a six-year low in 2025, it nevertheless remained above pre-pandemic levels for Massachusetts-based biopharma companies, according to MassBio. Money flowing into biopharma slowed to a trickle in 2025. But even as venture capital dropped to its lowest level in years, analysts have spotted hopeful signs, offering encouragement that funding could pick up in 2026. Across Massachusetts—one of biopharma’s central hotspots—venture capital (VC) i

Biotech showed 85% patient improvement in Phase 2a trial—zero approved treatments exist for persistent concussion symptoms BOSTON , Jan. 7, 2026 /PRNewswire/ -- Oxeia Biopharmaceuticals today launched an equity crowdfunding campaign on StartEngine to advance OXE103, a therapy for persistent concussion symptoms that demonstrated an 85% responder rate in Phase 2a clinical testing. The company is targeting Phase 2b enrollment of 160 patients beginning in 2026, positioning OXE103 as what could bec

First patient dosed and study open in leading oncology centers in US and Australia Phase I/IIA adaptive study aims to assess and optimize the dose of OTP-01 and provide safety, tolerability, and early efficacy data initially in patients known to benefit from PD-1 and/or VEGF treatment IND application data supports the potential of OTP-01 as a differentiated, next-generation antibody with potent PD-1 inhibition and unique VEGFR2 receptor inhibitory properties driving improved immune modulation an

Promising Hydrogel Could Help Kids Walk Again and Adults Avoid Invasive Surgery Dallas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Every year, thousands of children and adults face the crippling effects of osteonecrosis. Now, thanks to a $1.54 million NIH grant, researchers at Scottish Rite for Children and UT Southwestern Medical Center are studying a promising new treatment using hydrogel. Osteonecrosis is a painful condition where reduced blood flow causes bone tissue to die, which leads to the bone c

Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety pro growing performance benefits Primary safety endpoint met and encouraging secondary performance objectives at 6 months (in 94 patients) and 12 months (in 25 patients) REGENERA™ achieved high levels of patient and surgeon satisfaction Patients to be followed for up to five years to assess long-term safety First regulatory approvals in the EU expected in early 2027 Tensive in San Francisco during the JP

Company has built one of the largest proprietary extracellular matrix (ECM) datasets spanning fibrosis and solid tumors LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd (“Engitix”), a biotech company targeting the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, today announced the closing of a $25 million Series A extension financing, by Netherton Investments, a fund investing on behalf of Mike Platt, the co-founder and Managing Director of BlueCrest